ER Stress Signaling Promotes the Survival of Cancer “Persister Cells” Tolerant to EGFR Tyrosine Kinase Inhibitors

• Published in: Cancer research (Chicago, Ill.) Vol. 78; no. 4; pp. 1044 - 1057
• Main Authors: Terai, Hideki, Kitajima, Shunsuke, Potter, Danielle S., Matsui, Yusuke, Quiceno, Laura Gutierrez, Chen, Ting, Kim, Tae-jung, Rusan, Maria, Thai, Tran C., Piccioni, Federica, Donovan, Katherine A., Kwiatkowski, Nicholas, Hinohara, Kunihiko, Wei, Guo, Gray, Nathanael S., Fischer, Eric S., Wong, Kwok-Kin, Shimamura, Teppei, Letai, Anthony, Hammerman, Peter S., Barbie, David A.
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research, Inc 15.02.2018
• Subjects: Addictions; Animals; Bcl-x protein; Cancer; Cell Line, Tumor; Cell survival; Cell Survival - drug effects; CRISPR; Drug tolerance; Epidermal growth factor receptors; Genomes; Humans; Inflammation; Kinases; Lung cancer; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Mice; Principal Component Analysis - methods; Protein folding; Protein Kinase Inhibitors - therapeutic use; Signal Transduction; Transcription; Tyrosine kinase inhibitors

An increasingly recognized component of resistance to tyrosine kinase inhibitors (TKI) involves persistence of a drug-tolerant subpopulation of cancer cells that survive despite effective eradication of the majority of the cell population. Multiple groups have demonstrated that these drug-tolerant p...